Circulating tumor cells as an early predictive marker of disease progression in metastatic breast cancer patients

Algizawy, Samy M; Essa, Hoda H.; Elgezawy, Ebtesam; Omar, Nasiroh; Sayed, Douaa

doi:10.1093/annonc/mdw365.11

Cited by 2 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the treatment of breast cancer is surgery-based comprehensive treatment,the survival bene t from primary surgery may be related to the following conditions: 1. Surgery can remove the primary tumor site, get rid of the primary tumor cell and tumor stem cells, and reduce the possibility of peripheral release and spread of circulating tumor cells [24][25][26] ; 2. Primary surgery can play an important role at local control of on patients: Tumor ulcer, infection and other aspects ,which improving patients' physical and psychological quality of life; 3.…”

Section: Discussionmentioning

confidence: 99%

Impact of Surgery on Survival in Breast Cancer with Bone Metastases: a SEER database retrospective analysis

Peng

chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose It was controversial to operate on the primary site of breast cancer with simple bone metastasis，we found that the surgery could improve survival in patients with breast cancer with bone metastases via a SEER database retrospective analysis.Method Totolly 2917 cases of breast cancer with bone metastasis, first diagnosed between 2010 and 2015 in the National Cancer Institute surveillance, Epidemiology, and Results Database (SEER).We assessed the effect of different surgical procedures on survival and prognosis by the correlation statistics.Results Compared with the non-surgical group , the prognosis of patients on the primary tumor surgical group shows the statistical significance (c2 = 146.023, P < 0.001), the survival benefit of the breast-conserving group was the highest for 70 months(c2=157.117,P<0.001). Compared with the non-surgery group, the median OS of primary surgery group was: HR=0.525, 95%CI=0.467-0.590,P<0.001. In the breast-conserving group, the median operative OS: HR=0.394, 95%CI=0.325-0.478,P<0.001. Conclusion: This study showed that primary surgery could improve the prognosis and overall survival of women with advanced breast cancer with bone metastasis alone. Under the condition of low tumor burden, breast conserving surgery was a better choice.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of Surgery on Survival in Breast Cancer with Bone Metastases: a SEER database retrospective analysis

Peng

chen

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…It suggested that the count of CTCs can reflect the therapeutic effect and the survival of cancer patients (23,24). Meanwhile, Algizawy, et al carried out a study by enrolling 85 breast cancer patients and confirmed that the count of CTCs can be used as an auxiliary means to monitor the progress of the disease (25).…”

Section: Introductionmentioning

confidence: 99%

“…Meanwhile, Algizawy, et al. carried out a study by enrolling 85 breast cancer patients and confirmed that the count of CTCs can be used as an auxiliary means to monitor the progress of the disease ( 25 ).…”

Section: Introductionmentioning

confidence: 99%

Distribution and Clinical Analysis of EpCAM+/Vimentin+ Circulating Tumor Cells in High-Risk Population and Cancer Patients

et al. 2021

View full text Add to dashboard Cite

Circulating Tumor Cells (CTCs) are already present in the peripheral blood of patients with early tumors and even precancerous lesions. The objective of this study was to determine the count of CTCs in peripheral blood from high-risk population(HRP), healthy subjects and patients with Pan-cancer. The CTCs in the peripheral blood from HRP and cancer patients were enriched and identified based on the positive sorting method by epithelial cell adhesion molecular (EpCAM) liposome magnetic bead (Ep-LMB) and Vimentin liposome magnetic bead (Vi-LMB). Simultaneously, further analysis was carried out focusing on the clinical characteristics of patients by collecting the peripheral blood samples from healthy subjects as the parallel control. According to the results, the prepared LMBs had high specificity and stability, resulting in an average (Av) proliferation rate of over 90% for each cell line, and the average capture rate of higher than 80%. In terms of CTCs count detection in clinical blood samples, the average count was 0.9 (Ep: Av=0.6, Vi: Av=0.3), 2.4 (Ep: Av=1.4, Vi: Av=0.8) and 7.3 (Ep: Av=4.0, Vi: Av=3.3) in healthy subjects, HRP and total cancer patients, respectively. Besides, there was no obvious difference in the average count of CTCs among patients with different cancer types. While count of CTCs in the aforementioned cancer patients was statistically different from that in healthy subjects and patients with HRP. The survival time of cancer patients whose number of CTCs is greater than the average is significantly increased. Collectively, the study confirmed that CTCs can achieve early tumor detection and auxiliary diagnosis, and its number is related to the occurrence and development of tumors, and CTCs can be detected in HRP and sub-health population.

show abstract

Circulating tumor cells as an early predictive marker of disease progression in metastatic breast cancer patients

Cited by 2 publications

References 27 publications

Impact of Surgery on Survival in Breast Cancer with Bone Metastases: a SEER database retrospective analysis

Impact of Surgery on Survival in Breast Cancer with Bone Metastases: a SEER database retrospective analysis

Distribution and Clinical Analysis of EpCAM+/Vimentin+ Circulating Tumor Cells in High-Risk Population and Cancer Patients

Contact Info

Product

Resources

About